
Pacific Biosciences of California rose 17.2% from $1.57 to $1.84, ahead of the S&P 500's +11.2%. Its worst day was Oct 8 (−15.4%), and its low came Aug 12 at $1.11.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Pacific Biosciences of California shares rose 18.1%, while the S&P 500 rose 1.0%.
+18.1% · S&P 500 +1.0%
EPS of $-0.12 beat the $-0.16 estimate on $44.6M revenue (est. $41.8M).
Story events cover the past 12 months · Times ET
−7.1% · S&P 500 +0.1%
EPS of $-0.12 beat the $-0.14 estimate on $37.2M revenue (est. $40.2M); FY revenue guidance of $165.0M–$175.0M against the $174.6M consensus.
−14.5% · S&P 500 +0.8%
EPS of $-0.14 missed the $-0.13 estimate on $39.0M revenue (est. $41.0M); FY revenue guidance of $155.0M–$165.0M against the $167.4M consensus.
−10.4% · S&P 500 −0.2%
Pacific Biosciences of California shares rose 18.8%, while the S&P 500 rose 0.3%.
+18.8% · S&P 500 +0.3%
Pacific Biosciences of California shares rose 29.5%, while the S&P 500 fell 0.2%.
+29.5%, the year's best day, on 80M shares, the year's heaviest volume · S&P 500 −0.2%
Pacific Biosciences of California shares fell 15.4%, while the S&P 500 fell 0.4%.
−15.4%, the year's worst day · S&P 500 −0.4%
Pacific Biosciences of California shares rose 15.5%, while the S&P 500 rose 0.3%.
+15.5% · S&P 500 +0.3%
EPS of $-0.11 beat the $-0.13 estimate on $40.6M revenue (est. $39.1M); FY revenue guidance of $155.0M–$160.0M against the $158.2M consensus.
−4.7% · S&P 500 −4.4%
Where it ended: a close of $1.84 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-0.12, revenue est. $40.7M).
Nothing in the past 12 months.
All PACB dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PACB and SPY from Benzinga historical bars. Not investment advice.